OBJECTIVES: Redo cardiac surgery for aortic valve replacement (AVR) after previous coronary artery bypass grafting (CABG) is technically challenging and carries a high incidence of peri-operative complications. However, experience in the field continues to evolve generating reproducible, and increasingly safer results. We anticipate an increased future role for catheter-based valve procedures and review our operative results to maintain current surgical outcomes for comparison.
INTRODUCTION
The treatment of aortic valve disease is entering a new era. Transaortic valve implantation (TAVI) technology is evolving rapidly and promises an exciting future [1, 2] . Concurrently, established open surgical techniques exist that have been perfected over a half-century time-period and offer consistent, reproducible results [3, 4] . Future patient care will be optimized only if the best available techniques and technologies are objectively selected for application during the upcoming periods of evolution. For this to occur, continued, current, accurate procedural risk assessment is paramount.
Creation of a functional predictive model is difficult and frequently associated with inaccuracies. We acknowledge the efforts behind the European System for Cardiac Operative Risk Evaluation (EuroSCORE), The Society of Thoracic Surgeons (STS) database and various other risk prediction models in their attempts to achieve the stated goal. Each system is based on analyses of extensive collections of patient data. However, in facing such a difficult task, despite elegant design, these models overestimate risk. In fact, an overwhelming majority of studies suggest that this overestimation is consistent and often quite significant [3] [4] [5] [6] .
If the true risk to which patients are exposed is considerably different (lower) from that predicted, then proper patient selection does not occur. Evaluation of rapidly evolving technology is challenging. The purpose of our study was, first, to review our own experience with patients undergoing re-operative sternotomy for aortic valve replacement (AVR) after previous coronary artery bypass grafting (CABG) and second, to compare these results with STS models of risk prediction.
MATERIALS AND METHODS
This study was approved by our Institutional Review Board and is in full compliance with its policies and procedures.
A retrospective review was conducted from 1996 through 2010 of patients undergoing AVR as a re-operation after previous CABG by authors of the study. Data were obtained through query of our own institution's ( prospective) STS database and supplemented with chart review.
Clinical care for all patients was provided at one of two university-affiliated hospitals. Patients underwent uniform, standard preoperative work-up including coronary angiography. Conduct of the operation was performed according to surgeon preference and included both 'clamping' and 'no-clamping' techniques (in roughly equal proportions) for management of a patent left internal thoracic artery graft in conjunction with euthermia to mild hypothermia and included re-operative techniques as previously described [7] . Postoperative care was provided by the primary surgical team in a dedicated cardiac surgery intensive care unit setting.
Our institution's STS database served as the primary repository of patient data. It has been prospectively managed and audited by a team of full-time staff since 1996. Data were audited for accuracy at multiple levels including routine as well as supplemental chart review. Criteria for all data points are consistent with definitions used by the STS database concurrent to time of input [8] [9] [10] . All calculated STS risk scores correspond to modelling formulae applied at the time of surgery and do not represent any form of recalibration or retrospective application. Follow-up regarding late mortality was conducted using the Social Security Death Index and was 100% complete.
Study data are evaluated and reported in two parts. In the first part, patient characteristics, mortality and morbidity were examined and reported for all patients in the study (n = 132). The second portion of the study was designed to evaluate accuracy of risk prediction as calculated by the STS model. Two patient subsets (n = 111, n = 30) were examined (based on applicability of evolving versions of the STS predictive model that were available concurrent to the date of surgery) [8] [9] [10] . Since STS predictive models did not apply to all patients, study sample values represent only the fraction of patients who were capable of receiving calculated STS risk scores (n = 111, n = 30). The larger group was composed of the 111 patients who received an STS mortality risk score for AVR (n = 85) or AVR + CABG (n = 26). Patients who underwent additional 'other' procedures beyond AVR ± CABG [AVR + other (n = 10); AVR + CABG + other (n = 11)] were not supported by STS formulae for mortality risk calculation and, therefore, could not be included. Those patients undergoing CABG received a mean of 1.65 coronary grafts.
In 2008, the STS model adopted eight additional endpoints for the prediction of various complications beyond operative mortality [8] [9] [10] . These additional endpoints were: (i) permanent stroke, (ii) renal failure, (iii) prolonged ventilation, (iv) deep sternal wound infection, (v) re-operation for any reason, (vi) major morbidity or mortality 'combined', (vii) prolonged postoperative length of stay >14 days (alive or dead) and (viii) short postoperative length of stay <6 days ( patient alive at discharge). The last 30 patients in the study were eligible for evaluation by the newer 2008 STS model for risk prediction. For this group of 30, our patient outcomes were compared with corresponding STS predictive scores in all the above categories.
Statistical methods
Statistical analyses were performed using SAS software (Cary, NC, USA). Arithmetic means with 95% confidence intervals (CIs) were presented for continuous measures. Percentages with Wilson-refined 95% CIs were presented for dichotomous measures. The distributions of the STS predictions for individual patients were positively skewed and so the geometric mean and 95% CI were presented and contrasted with the actual percentages of events with their Wilson-refined 95% CIs. The KaplanMeier method was used to estimate the survival functions for time-to-event data. The Hosmer-Lemeshow lack of fit statistic was used to test whether the observed mortality rate was significantly outside that predicted by the STS using quintiles owing to the low mortality rate.
RESULTS
One hundred and thirty-two patients met inclusion criteria (male 83%, female 17%). Average age was 76.5 (±7.3). Thirty-seven patients (28%) required concomitant CABG. Additional key patient characteristics are presented in Tables 1  and 2 . Operative (30-day + hospital) mortality was 6.1% (8/132; 95% CI = 2.9-12.0%). Thirty-day mortality was 3.8% (5/132; 95% CI = 1.4-9.1%). The total number of deaths in the study was 62/132.
One, three and five-year survival rates were 86, 74 and 62%, respectively. Kaplan-Meier survival data are presented in Fig. 1 .
Complication rates were as follows: re-operation for bleeding 2.3% (3/132), permanent stroke 0.8% (1/132), prolonged ventilator requirement 18.2% (24/132), deep sternal wound infection 0% (0/132; CI = 0.0-3.5%) and renal failure 9.1% (12/132; none required dialysis). Additional details are presented in Table 3 . Median length of stay (surgery date to discharge date) was 9 (95% CI = 8-13) days (Fig. 2) .
One hundred and eleven patients fit criteria for the STS mortality risk prediction model. For this group (with a prospectively obtained STS risk score), the actual operative (30-day + hospital) mortality was 3.6% (4/111; 95% CI = 1.16-9.51%). The STS-predicted mortality score for the same 111 patients was: 7.8%; 95% CI = 6.8-9.0%. The difference between the observed and STS-predicted mortality approached statistical significance [Chi-square (3) = 7.25, P = 0.0644], though the extremely low mortality counts likely reduced our ability to detect this difference. These findings are contrasted in Fig. 3 . STS (2008 model)-predictive risk scores for nine endpoints were compared with observed study outcomes. Results represent a small number (n = 30) of the most recent patients and are therefore presented in Table 4 format without further analysis. A trend appears suggesting that STS-predicted scores are higher than observed results.
DISCUSSION
In the past, results of redo AVR after previous CABG were a focus of discussion due to uncertainty regarding operative indications for mild aortic stenosis at the time of primary CABG. Today relevance has shifted towards direct comparison with TAVI.
With regard to interpretation of our own outcomes, we make two general observations. First, operative results in this study are in line with previous reports [3, 4, [11] [12] [13] and suggest that 
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re-operation for AVR can be performed safely and successfully after previous CABG. Second, when comparing our outcomes data with prospectively obtained STS scores, we found that predicted risk was overestimated. Examination of the literature shows a range of reported operative mortality rates for patients undergoing re-operation for AVR after previous CABG [11] [12] [13] [14] [15] [16] [17] [18] . As expected, a steady trend towards improvement is observed historically. Low rates of reported mortality and morbidity strongly support a continued, current role for conventional AVR after previous CABG.
Surgical outcomes prediction models, such as EuroSCORE and STS score, aim to direct clinical care. Flawed prediction models, however, will generate incorrect risk assessment with subsequent translation into erroneous decision-making. Objective examination demonstrates that EuroSCORE and STS score significantly overestimate risk, though, it occurs to a lesser degree with the latter.
Di Giammarco et al. [19] documented that EuroSCORE overestimated mortality. In selected high-risk groups, the overestimation was quite pronounced leading the authors to conclude that EuroSCORE appears to be an 'invalid model' in risk prediction for AVR. Other studies have widely questioned the accuracy of EuroSCORE [20, 21] .
Studies examining predictive ability of the STS model similarly reveal flaws. Redlich et al. [3] achieved a 5% 30-day mortality in patients undergoing 'redo' AVR after previous CABG in a patient sample with a mean STS score of 19%. Khaladj et al. [4] operating under similar circumstances, reported a 5% 30-day mortality with a corresponding STS score of 10%. Frilling et al. [5] demonstrated overestimation of operative risk by the STS score in elderly patients undergoing AVR alone or in conjunction with CABG.
In both models, tendency to overstate risk has specifically been most pronounced in 'high-risk' patients. This trend towards significant errors in high-risk groups has been documented repeatedly and includes patients undergoing redo AVR after CABG [4, 5, 22, 23] .
The notion of a flawed STS prediction model is further supported by attempts to retroactively 'recalibrate' scores that are known to be incorrect. Jin et al. [6] explore the significance of 'raw' versus 'calibrated' STS scores and conclude that raw STS scores are particularly susceptible to overstatement. They advocate recalibration of STS scores in order to retroactively correct estimations of risk, describing that 'If used without calibration, the risk scores are almost always higher than they should be, thereby overstating risk and underestimating the O/E ratio.' Final recalibration appears impossible to ever achieve since even retroactive data corrections can subsequently affect future calibrations. Nonetheless, we know that recalibration most commonly serves to lower (slightly) previously calculated risk scores. Such retroactive corrections do not appear to be of a scale that would have a significant impact on the rather large discrepancies (between predicted and actual outcomes) documented throughout the literature (also ref. Fig. 3 ). More importantly, recalibration, due to its retrospective application, can serve no functional role in prospective patient risk evaluation preceding surgery. Inflated risk scores should not be used to label patients inoperable. There exists a growing trend in the use of surgical predictive risk models (designed for conventional AVR) for the preoperative assessment of potential TAVI patients. This is certainly neither the intended design nor best application. Rapid, continued TAVI improvements are uniformly anticipated. In the near future, therefore, TAVI outcomes will inevitably assume the role of a 'moving target.' Proper patient treatment selection, TAVI versus AVR, will depend on accurate risk assessment drawn on careful review of data and on the combined experience of cardiologists and cardiac surgeons.
Walther et al. [24] report a 30-day mortality rate of 12% for patients undergoing transapical aortic valve implantation after previous cardiac surgery (68% of patients represented previous CABG). They interpret these results as 'very good' in light of the fact that the patients were classified high-risk by a mean STS score of 18% (logistic EuroSCORE 39%). This group is a pioneer in the field, and such excellent outcomes are laudable given the complex procedures being performed and the challenging nature of patients requiring treatment. Nonetheless, the comparison that should be made is one with a contemporary study also from Germany. Redlich et al. [3] produced a 30-day mortality rate of 5% on a patient sample with an almost identical mean STS score of 19% (logistic EuroSCORE 27%) that underwent conventional AVR after previous history of CABG. Such direct comparison is the type that must be made as the course of evolving technologies is followed into the future. Indirect mortality comparisons to flawed prediction models generate inappropriate criteria for patient selection.
Limitations
In accounting for potential sources of bias, the role of statistical notation should be examined. Imprecise presentation of data as simple as central tendency can obscure results. The STS predictive scores in our sample were positively skewed as are most groups with high-risk patients acting as 'statistical outliers.' Accordingly, geometric (in contrast to arithmetic) mean and 95% CIs were used as an estimate of central tendency to account for positive skew. Use of arithmetic mean with our data would have produced an inaccurate value of >10% in contrast to more appropriate representations (geometric mean 7.8%, or median 8.2%). Improper representation of central tendency in reported data sets with statistical outliers may be one contributing factor to rampant overestimation of risk which is most pronounced in 'high-risk' groups. Observed mortality versus mortality predicted by STS score. All patients with an STS mortality score were included (n = 111) in this graph. Actual operative (30-day + hospital) mortality = 3.6% (4/111), 95% confidence intervals = 1.2-9.5%. STS-predicted operative mortality = 7.8% (geometric mean), 95% confidence intervals = 6.8-9.0%. Dark grey bar = arithmetic mean (10.28%), light grey bar = median (8.23%); note: use of arithmetic mean as an estimate of central tendency would have generated a number >10%. Bias can also be introduced through the process of patient selection (for surgery). There probably exists some degree of preferential identification of patients who were deemed by the surgeon to be reasonable operative candidates. Though objective predictive models can form a basis for patient selection, the final decision regarding surgery has a highly subjective component rooted in the surgeon's experience and judgment regardless of any calculated predictive risk score. Any interpretation of data must also account for the study's retrospective nature and 15-year time span, during which surgical techniques have improved and patient profiles have changed. Furthermore, as the reader knows, TAVI was not available during a large portion of this study and may have affected patient selection once it became available.
CONCLUSIONS
We feel that the surgical results presented in this study fall in line with those of others and support the use of conventional AVR after previous CABG as a time-tested technique. As do others, we eagerly anticipate the upcoming rapid evolution of TAVI. While much attention in the literature will focus on new technologies, it is important to remember that conventional surgery continues to offer a viable option, consistently produces good results and remains the gold standard for re-operative AVR after previous CABG.
APPENDIX. CONFERENCE DISCUSSION
Dr A. Bogers (Rotterdam, Netherlands): You report on 132 patients with AVR after coronary surgery that was previously performed by one of your co-authors, as described. It is not clear why you did not include all AVRs after coronary surgery in your centre, and no information is given on possible AVRs elsewhere, or on patients rejected for AVR or referred for TAVI, and apparently no patients with low ejection fraction are included. In addition, the surgeon's discretion determined the indication for surgery, and your manuscript does not provide the guidelines used or the heart team approach. In your STS model studies, you had to exclude 21 of 132 patients in one arm of the study and could include only 30 in the last part of your study.
Nevertheless, I very much liked your general remarks, who can refute them, that inflated risk scores should not be used to label patients inoperable, and especially not in relation to TAVI treatment, and also the remark that so-called good TAVI results should not be compared to STS or EuroSCORE but to actual surgical results. I think we all agree. However, I am afraid that your patient selection and your limited study size are not of adequate strength to support these conclusions.
It would be much more accurate to use sufficiently large and complete data sets. Could you comment on that? And I have two small additional questions. Question two: what was the time interval between the CABG and the AVR? It was not included in your manuscript and not in your slides. And question three: did you start working with the heart team approach in this regard?
Dr Dobrilovic: Which approach? Dr Bogers: The heart team approach. Dr Dobrilovic: Just to clarify concerning the patients in the study and inclusion criteria, and especially the 111 patients, we attempted to include all patients within the risk model, which would be 132. Unfortunately, the STS risk model cannot include certain patients. They support CABG or AVR separately or AVR/CABG. They do not support a third other procedure. So, for example, if somebody had an AVR/CABG plus a mitral valve or aortic replacement, these would fall out because a prediction model does not exist. Those represent probably a higher mortality patient, in any case. But that is the reason why they were not included. The study was driven entirely by the STS database and is 100% inclusive of all patients that could be included. It was not a single-surgeon study, I don't know if that was clear in the presentation, but it represents a study by multiple authors. Regarding the technique, the clamping and no-clamping techniques are determined by surgeon preference, and they are roughly 50-50 in our institution, and it was up to the surgeon's discretion. In relation to the interval, we do not have information regarding the interval, as a lot of patients were referred from outside our hospital and it is not a data set that we looked at.
Dr Bogers: The heart team approach: do you have a heart team working at your hospital?
Dr Dobrilovic: In which sense, heart team? Dr Bogers: Apparently the answer is "no" then. The heart team discusses the indications for surgery. The indications for surgery in your study are at the discretion of the attending surgeon, as I understood from your paper.
Dr Dobrilovic: To clarify, we work very closely with our cardiologists, and on these types of cases especially, have a serious discussion with both the cardiologist and the patient regarding what would be the best operation. It is not a formal "heart team", but we work in very close conjunction with Cardiology. All of these patients were discussed with multiple teams.
Dr Bogers: And what happens to patients with a low ejection fraction in this setting? The average ejection fraction was 42, plus or minus a certain percentage, but what happens to those with a lower ejection fraction?
Dr Dobrilovic: That does represent a lot of patients with low ejection fractions. That was just the average. But they are discussed as well on an individual basis and a determination is made.
Dr G. Lutter (Kiel, Germany): These excellent results in an average patient cohort tell us that we do not have to put a transcatheter aortic valve stent into those patients.
